Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data.

Biomed Res Int · 2018 · PMC6311249 · PMID 30643823

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

might be significantno p-value reported

If the answer is yes, then there might be significant baseline difference between elotuzumab arm and carfilzomib arm, which may interfere with the treatment effect thus make the interpretation of our findings very difficult.

also in 2,428 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.